The Global HIV Vaccine Enterprise by José Esparza
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Summary. AIDS, which twenty-five years ago no one even knew it existed, has
become the most serious infectious disease worldwide. The development of an
HIV vaccine is one of the most difficult challenges that modern biomedical science
is confronting. To address this challenge, scientists may need to organize them-
selves in a more intense, targeted, and collaborative effort, such as the one pro-
posed by the Global HIV/AIDS Vaccine Enterprise. The enterprise concept propos-
es to complement the creativity of individual investigators with a collaborative sys-
tem that ensures a more effective use of human and financial resources to produce
new scientific knowledge. It also implies that the scientific knowledge can be har-
nessed in a targeted way to develop practical solutions to urgent global health prob-
lems, including explicit product development activities. Different modalities of the
enterprise concept are being explored for the development of drugs to treat tuber-
culosis and vaccines to prevent malaria. [Int Microbiol 2005; 8(2):93-101]
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The HIV/AIDS pandemic
AIDS was first reported in a short article published in 1981
in the Mortality and Morbidity Weekly Report of the US
Centers for Disease Control and Prevention. [5]. The article
described cases of Pneumocystis carinii pneumonia in five
homosexual men in Los Angeles [13]. One month later 26
cases of Kaposi sarcoma among gay men were reported in
the same newsletter [6], and that started a chain reaction with
new cases of this acquired immunodeficiency being identi-
fied in different parts of the world.
After a period of initial confusion, the etiology of this
new disease was clarified when Luc Montagnier [2] and
Robert Gallo [12] provided complementary evidence indicat-
ing that a new retrovirus was associated with the disease that
today is called AIDS. Very soon masses of information on
HIV accumulated, building on an extensive body of knowl-
edge on retroviruses, generated mostly from research sup-
ported in the 1970s as part of the so called “war on cancer”.
This is an extremely interesting example of how investments
in a particular area of research can produce incredible bene-
fits in a totally unexpected and unrelated field. With the iso-
lation of HIV, diagnostic tests were rapidly developed, and
the first serological test was licensed in 1985 [3]. Widespread
serological screening made it possible to better understand
the spread of the virus and to initiate a global response
against that pandemic. In 1987 the first ant-HIV drug, AZT
or zidovudine, was licensed [15]. This was the first of a long
list of antiretroviral drugs that, used in combination, have
dramatically changed the prognosis of people living with
HIV/AIDS, at least in rich countries where people have
access to these treatments.
In the last twenty-four years, HIV has continued its
relentless spread and today it is estimated that around 40 mil-
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lion people are living with HIV/AIDS in the world, and that
more than 20 million people have already died of AIDS
(Table 1). All of this from a disease that only 25 years ago we
did not even know existed. 
Of the estimated 40 million people living with HIV/AIDS
in the world, 95% of them lives in developing countries,
especially in Africa, which is home to 26 million people
already infected with HIV. In at least six Sub-Saharan
African countries, one in five adults are already infected with
HIV, and in another ten countries 10 per cent of adults are
infected. Contrary to popular belief, the epidemic is not
under control. HIV continues to spread relentlessly at a rate
of 14,000 new HIV infections every day [19].
The Joint United Nations Programme on HIV/AIDS,
UNAIDS, has forecasted that from now until 2010 we could
be adding some 5 million new infections every year. At the
same time, we must recognize that we have some tools
(although not the optimal ones) to try to prevent many of
these infections. UNAIDS estimates that a comprehensive
global response to the epidemic could reduce the number of
new infections to less than 2 million per year. However, that
comprehensive response would require an investment in
developing countries in the order of 15 to 20 billion dollars per
year, which any of them cannot possibly afford. The sad reality
is that fewer than one in five people at risk of HIV infection
worldwide have access to prevention interventions, and less
than 7 per cent of HIV-infected people have access to treatment. 
Considering the logistical difficulties that the world is
encountering in increasing and maintaining access to existing
preventive interventions, an HIV vaccine may represent the
best long-term solution for controlling the HIV/AIDS pan-
demic. It is indeed a long-term solution because developing
an HIV vaccine remains one of the most difficult challenges
confronting biomedical research today. As Ron Desrosiers
commented in Nature Medicine, our struggle to develop an
HIV vaccine can be compared to the mythical punishment of
Sisyphus, condemned by the gods to roll a rock to the top of
a mountain for eternity [10]. 
Confronting new scientific challenges in the search for an
AIDS vaccine, and there are many, is usually frustrating, and
some people wonder whether an HIV vaccine can be ever
developed and whether scientists should give up that line of
research and try to control this epidemic with other interven-
tions, although they obviously are not the solution.
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Table 1. Regional HIV/AIDS statistics and features, end of 2004*
Region Adults & childrenliving with HIV
Adults & children
newly infected 
Adult prevalence
rate (%)1
Adult & child deaths
due to AIDS
Sub-Saharan Africa 25.4×106
[23.4–28.4 × 106]
3.1 × 106
[2.7–3.8 × 106]
7.4
[6.9–8.3]
2.3 × 106
[2.1–2.6 × 106]
North Africa &
Middle East
540 000
[230 000–1.5 × 106]
92 000
[34 000–350 000]
0.3
[0.1 - 0.7]
28 000
[12 000–72 000]
South & South-East
Asia
7.1 × 106
[4.4–10.6 × 106]
890 000
[480 000–2.0 × 106]
0.6
[0.4–0.9]
490 000
[300 000–750 000]
East Asia 1.1 × 106
[560 000–1.8 × 106]
290 000
[84 000–830 000]
0.1
[0.1–0.2]
51 000
[25 000–86 000]
Latin America 1.7 × 106
[1.3–2.2 × 106]
240 000
[170 000–430 000]
0.6
[0.5–0.8]
95 000
[73 000–120 000]
Caribbean 440 000
[270 000–780 000]
53 000
[27 000–140 000]
2.3
[1.5–4.1]
36 000
[24 000–61 000]
Eastern Europe &
Central Asia
1.4 × 106
[920 000–2.1 × 106]
210 000
[110 000–480 000]
0.8
[0.5 - 1.2]
60 000
[39 000–87 000]
Western & 
Central Europe
610 000
[480 000–760 000]
21 000
[14 000–38 000]
0.3
[0.2–0.3]
6 500
[<8 500]
North America 1.0 × 106
[540 000–1.6 × 106]
44 000
[16 000–120 000]
0.6
[0.3 - 1.0]
16 000
[8 400–25 000]
Oceania 35 000
[25 000–48 000]
5 000
[2 100–13 000]
0.2
[0.1–0.3]
700
<1 700
TOTAL 39.4 × 106
(35.9–44.3 × 106)
4.9 × 106
(4.3–6.4 × 106)
1.1%
(1.0–1.3%)
3.1 × 106
(2.8–3.5 × 106)
*Adapted from: World Health Organization (2005). Facts about HIV/AIDS-Global. [http://w3.whosea.org/EN/Section10/Section18/
Section348.htm#Global]
1The proportion of adults (15 to 49 years of age) living with HIV/AIDS in 2004, using 2004 population numbers. The ranges around the esti-
mates in this table define the boundaries within which the actual numbers lie, based on the best available information.
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The quest for an HIV vaccine
When HIV was identified as the causal agent of AIDS, the
scientific community was optimistic in relation to the rapid
development of an HIV vaccine. In fact, virologists have
been very successful developing vaccines against many other
viral diseases. That optimism led to a famous press confer-
ence in 1984, where Margaret Heckler, then the US secretary
of Health, predicted that an HIV vaccine would be in clinical
trials within the following two years. Secretary Heckler was
right because in 1987 the first phase I trial of an HIV vaccine
was initiated, using a baculovirus-derived gp160 manufac-
tured by MicroGeneSys. What Mrs. Heckler did not know, as
not any one knew at that time, was that HIV was much more
complex than any virus or disease against which vaccines
had been successfully developed.
The scientific issues about the difficulty in developing a
HIV vaccine will not be discussed here, but they are mostly
related to the fact that the immune response against HIV fail
to control viral replication or progression to disease, and this
is compounded by the extremely high rate of genetic variabil-
ity of HIV, which facilitates escape of what otherwise could
be an effective immune response. Nevertheless, and despite
these scientific uncertainties, several candidate vaccines
were developed and tested in human trials between 1986 and
1997. With renewed optimism, President Clinton proclaimed
in 1997 the national goal of finding a vaccine for AIDS with-
in the next ten years. He acknowledged, however, that that
task was going to be difficult, and compared it with President
Kennedy’s call to put a man on the moon before the end of
the 1960s. Despite important progress made since 1997, it
has now become evident that President Clinton’s deadline of
2007 will not be met.
Vaccine studies are carried out in several phases. The first
two phases consist of small trials whose aim is to confirm the
safety and immunogenicity of the candidate vaccine as well
as to determine the most effective dosage and schedule in a
given population. Phase III trials, which test the vaccine for
protective efficacy, are carried out only if the results of phas-
es I and II have shown that the vaccine is safe and promising.
In 2003 the HIV vaccine study conducted by VaxGen
(Brisbane, California) was the first to conclude a phase III
trial. Unfortunately, the candidate vaccine, a genetically
engineered version of the HIV surface protein gp120, failed
to provide any significant protection against HIV infection or
disease [7]. These results had been predicted by many scien-
tists, but “the proof is in the pudding”, and there is no
replacement for well conducted clinical trials to obtain defin-
itive information on the efficacy of any vaccine.
Three waves of vaccine paradigms 
and clinical trials, and current 
HIV vaccine concepts
Almost twenty years of research have led to the current HIV
vaccine concepts shown in Fig. 1 [11]. Whole inactivated and
live attenuated viruses, which are the classical approaches for
viral vaccine development, are not being seriously consid-
ered for a human vaccine due to significant safety concerns.
So, the majority of the candidate vaccines under develop-
ment are based on subunit vaccines. Some of these subunit
vaccines are based on the envelope proteins of HIV (espe-
cially gp120) or on selected epitopes of these proteins, and
these vaccines are mostly aimed at inducing neutralizing
antibodies. The VaxGen product that failed to induce protec-
tive immunity in phase III trials was based on a monomeric
form of gp120. Other candidate vaccines use naked DNA or
different bacterial or viral vectors, and they are designed to
induce cell mediated immunity especially targeted to the
internal more conserved proteins of HIV. And, some of these
candidate vaccines are being explored in different prime-
boost combinations, with the idea of inducing both humoral
and cell-mediated immune responses
We can consider three waves of vaccine paradigms and
clinical trials in the history of HIV vaccines. The first started
with the discovery of the virus itself, and was based on the
concept that neutralizing antibodies alone could be sufficient
to induce protective immunity. Envelope-based vaccines
were designed to induce neutralizing antibodies. This wave
was completed in 2003, with the negative results of the
gp120 phase III trials [7]. Overlapping the first wave, the sec-
ond one started in the mid 1990’s, with the recognition that
cell-mediated immunity was a major component of the pro-
tective immune response against HIV infection, and this led
to the development of DNA and vectored vaccines, three of
which are now entering large scale trials, including poxvirus
and adenovirus vectors in different prime-boost combina-
tions. And we are now entering the third wave of HIV vac-
cine development, with the paradigm that we need new vac-
cine concepts and combinations, to induce more potent and
durable humoral and cell-mediated immune responses, capa-
ble of preventing infection by primary isolates of different
HIV subtypes.
From these almost twenty years of research, we have had
some lessons. The first lesson is that the initial generation of
envelope-based vaccines failed to induce protective immuni-
ty, and that novel envelope-based constructs will need to be
developed and tested with the hope that they will induce the
right quality and quantity of neutralizing antibodies. Like-
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needed because the present effort is not sufficient to produce
a vaccine in the foreseeable future. This is because of the
many scientific uncertainties that we are facing, and of insuf-
ficient investment, especially from the private sector. The
article also outlines a new game plan for a more collaborative
HIV vaccine discovery effort. Of course, we fully recognize,
that it is not possible to plan for discovery, but we can indeed
plan for the research that may accelerate discovery.
Basic principles. The severity of the AIDS pandemic and
the need to maintain the momentum of our response to the pan-
demic is another major justification for the Enterprise, espe-
cially when the world is getting used to AIDS, which could
become considered as just another “tropical disease” that does
not affect “us”; or that the problem has already been solved
with the development of antiretroviral therapies; and we also
need to neutralize potential discouragement due to the percep-
tion that, perhaps, the development of an HIV vaccine is just
not possible. Finally, the Enterprise is proposed because the
urgency of the epidemic requires a more rapid vaccine devel-
opment strategy, and this process involves very high costs, and
very high risks that impose the need to identify new strategies
for collaborative partnerships between the public and private
sector and between industrialized and developing countries. 
The Enterprise concept means a new way of thinking
about problems, with the formulation of shared strategic
plans, which have a level of “strategic vagueness” that should
allow for self-learning and self correcting. It also means a
new way of acting to solve problems, using common tools
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wise, the first generations of T-cell vaccines, which are the
majority in clinical trials today, only induce low level of
immunity and of short duration. Additional research is need-
ed to develop more potent vectors, especially those that can
induce long-term memory. Two areas which are relatively
unexplored, but that could provide some interesting leads in
the future are those of mucosal and innate immunity. Finally,
we are still struggling with the relevance of primate protec-
tion experiments in relation to potential protection in
humans. We are not sure how to use these primate models as
gate-keepers for moving candidate vaccines to clinical trials.
Continuing HIV vaccine research doing more of the same
with the hope that one day or other an effective safe vaccine
will come out has no sense. New paradigms on how conduct
HIV vaccine research must bee explored.
The Global HIV Vaccine Enterprise
In the context of one of major epidemics humankind is con-
fronting, and searching for a new way of doing things, a
group of twenty-four scientists, including two Nobel laure-
ates (Harold Varmus and David Baltimore), proposed in June
2003 the creation of a global HIV vaccine Enterprise. The
lead author of the paper was Rick Klausner, former director
of the National Cancer Institute and current Executive
Director for Global Health at the Bill & Melinda Gates
Foudation, which has been one of the main driving forces of
this initiative [14]. The article argues that the Enterprise is
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Fig. 1. Current HIV vaccine
concepts. Based on WHO and
UNAIDS.
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and optimized resources, and supporting iterative activities
that will lead to incremental knowledge. Finally, it means a
new way of behaving as a global community of problem-
solvers, that actively share information, that defer decisions
to evidence rather than to advocacy, and that develop activi-
ties with the correct balance between collaboration and com-
petition, both of which are major driving forces in the scien-
tific endeavor.
The year 2003 was the period of conceptualization of the
Enterprise, with the publication of the proposal in Science,
and a follow-up meeting to refine the vision of the Enterprise.
The year 2004 was spent in planning the implementation of
the Enterprise vision, including the development of a joint
Scientific Strategic Plan, and seeking the high level political
support that will be necessary to obtain the resources to
implement the identified priority activities. And in 2005 sev-
eral activities are starting which include a new NIH Center
for HIV/AIDS Vaccine Immunology (CHAVI), as well as a
fresh infusion of funds from the Bill & Melinda Gates
Foundation. The vision of the Enterprise was refined at a
meeting convened by the authors of the Enterprise proposal
plus a group of leading scientists, public health experts, and
policy makers, which took place at the Airlie House in
Warrenton, Virginia, in August 2003. The group agreed that
the Enterprise would be developed, not as a new organiza-
tion, but as an alliance of independent organizations (includ-
ing funders and implementers) committed to accelerating the
development of a preventive vaccine for HIV through the
implementation of a jointly developed scientific plan, mobi-
lization of additional resources, and greater collaboration
among HIV vaccine researchers worldwide.
The Airlie House vision put the jointly developed scientific
plan at the center of the proposed Enterprise, and this shared
plan will be financially supported and technically implemented
by a number of independent and autonomous institutions, with
their own budget and using their own decision making mecha-
nisms. So, as I indicated before, the Enterprise is not a new
organization but an alliance of like-minded partners committed
to accelerating the search for an AIDS vaccine.
The Enterprise is being developed, to some extent, fol-
lowing the model which was used to put together the success-
ful Human Genome Project: many founders agreed on a sci-
entific road map, voluntarily divided the work, and agreed
also to an evolving set of production standards. The main fea-
tures of the road map for the Global HIV Vaccine Enterprise
are (i) the priorization of the scientific challenges to be
addressed as well as product development efforts, (ii) the
rapid development of an implementation plan for all the com-
ponents of the system, and (iii) the development of a plan that
identifies the resources needed [14].
Several political bodies have already endorsed the
Enterprise. In June 2004, the leaders of the industrialized
countries (the G8) signed a communiqué expressing their
belief that the time was right for the major scientific and
other stakeholders to come together in a more organized
fashion, and they endorsed the concept and called for the
establishment of the Global HIV Vaccine Enterprise.
Scientific Strategic Plan. The scientific plan of the
Enterprise was developed through a process of consultation
in which six working groups involved more than 120 partic-
ipants from 15 countries, and the plan was published in
February 2005 in the open-access journal Public Library of
Science, Medicine [8]. The plan summarizes the identified
scientific priorities in the areas of vaccine discovery, labora-
tory standardization, product development and manufactur-
ing, clinical trial capacity, regulatory considerations, and
intellectual property issues. It also describes strategies and
activities to implement the scientific agenda, including a dis-
cussion of the guiding principles of the Enterprise, a possible
organizational structure, funding issues and political support.
Although we are just beginning to implement the plan, some
related activities are already starting, including the establish-
ment of a permanent secretariat, to facilitate the coordinated
funding and implementation of the plan by the different part-
ners of the Enterprise alliance (Fig. 2).
Activities from the Bill & Melinda Gates
Foundation. The Gates Foundation announced its deci-
sion to support the creation of centers or consortia focusing
on vaccine discovery and laboratory standardization, which
will work not as individual isolated groups, but as a network
of institutions engaged in active and intense collaboration,
according to the Global HIV/AIDS Vaccine Enterprise. With
this model we hope to harness the best of both worlds, the
creativity of individual investigators and the dimension,
energy and sense of purpose of a big-science collaborative
Enterprise.
In response to a call for proposals from the Gates
Foundation to establish these targeted research centers, a
number of pre-proposals (letters of inquiry) were received,
focusing on one or a small number of new ideas, and bring-
ing together the necessary variety, innovation and expertise
to solve the specific problem proposed. A network analysis of
the pre-proposals showed that many of the laboratories were
highly interlinked among themselves, with a smaller number
of unlinked groups which may represent those working out-
side of the research mainstream. The exchange of informa-
tion is crucial for each laboratory to be as productive as pos-
sible, and to share reagents and procedures, so that data can
HIV VACCINE
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for basic knowledge, and the later by the search for solutions.
Again, there is no real tension. Both driving forces of science,
the quest for fundamental understanding and the considerations
for the use of the research results, are not only equally impor-
tant but often they are also mutually energizing.
Evolution of the scientific enterprise
With the ever increasing complexity of science, and the
increasing difficulty of the problems to confront and to solve,
scientific research has evolved into a highly complex enter-
prise with multiple partners that need to work in well coordi-
nated fashion. That concept was recently discussed in the
journal Science by Albert-László Barabási in a short com-
mentary on the network theory and the emergence of the sci-
entific enterprise (no relation with Global HIV Vaccine
Enterprise) [1]. Barabási described how most great thinkers
of the past published alone, although they built on each
other’s work and communicated with each other, as part of
what Derek De Solla Price called “the invisible college” [9]. In
the twentieth century, science became an increasingly collabora-
tive enterprise, but usually of small groups, and the “invisible
college” began to take formal shape and to become more visible. 
More recent developments have led to larger collabora-
tions, such as the International Human Genome Sequencing
Consortium. Barabási recognized, however, that it was high-
ly improbable that such large collaborations would come to
dominate science, but he also recognized that most fields
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be compared and, whenever necessary, analysed together [8].
A network of Clinical Research Training Centers in develop-
ing countries could help to ensure the quality of trials. In
addition, a network of individuals and companies with man-
ufacturing experience could link to consortia, centers and
others providing them with process development and manu-
facturinmg expertise.
Issues or tensions in the development of the
Enterprise concept. One tension which could arise in
such an Enterprise project could be between what some peo-
ple calls “group thinking” and “individual thinking”. This
tension has been presented occasionally as two different
ways of doing science. One way is entirely based on the cre-
ativity of individual investigators working more or less in
isolation on their own labs (what could be called the RO1
NIH culture). And the other way, where scientific exploration
is guided by the collective wisdom of experts. History has
taught us multiple times that current expert opinion is not
always the right one. But, in fact, there is not real tension
between these two ways of doing science; a more purposeful
game plan can increase the individual creativity of
researchers. In a war, soldiers are not sent to fight their own
little battles. They are sent with a well prepared plan to opti-
mize their individual efforts. And we are in a battle against
AIDS.
The other tension, related to the first one, could be
between investigator-driven basic research and targeted
research, where the first is driven by curiosity and the search
Fig. 2. Linkages between laboratories working
on HIV vaccines.In
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need such collaborations and that the size of collaborative
teams has increased, turning the scientific enterprise into a
densely interconnected network driven by simple universal
laws of efficiency that need to be understood, not ignored.
One of the laws Barabási mentioned suggests that when
forming a “dream team” an effort should be made to avoid
the temptations to work mainly with friends that may not be
the best scientists in the field, because that could eventually
hurt the overall performance of the effort. In summary, the
idealized image of the lonely investigator working in isola-
tion in his or her lab, has now been replaced, or at least com-
plemented, by a more collaborative effort such as the one
suggested by the Global HIV Vaccine Enterprise.
The other argument frequently mentioned is that individ-
ual thinking is more creative than group thinking. However,
that argument fails to capture the concept of “current scien-
tific paradigm”, or “common science”, originally proposed
by Thomas Kuhn [16]. Kuhn argued that the scientific com-
munity is extremely homogenous and very conservative. It is
composed by members that go to the same schools, attend the
same conferences, read the same journals, and that have their
papers and grants peer-reviewed and hopefully accepted or
approved by the same people. According to Kuhn, this situa-
tion creates a paradigm of “common science” that is not
entirely conducive to innovation.
Pushing really innovative ideas, “out-of-the-box” ideas is
actually risky. If they are ever funded (which is not often the
case) they have a high risk of failure. But, on the other hand,
the same community that is so risk-adverse, at the same time
puts a high value on creativity and innovation. According to
Kuhn, real scientific progress occurs when a new paradigm
emerges that is more satisfactory than the current paradigm
that drives the work of the scientific community. Then, Kuhn
argued, when the new paradigm replaces the old one, scien-
tists are rarely convinced to adopt the new ideas, and the new
paradigm is fully adopted only when the old scientists die,
and the younger scientists adopt the more satisfactory new
paradigm which, with time, will become the “common sci-
ence”, waiting to be superseded by a future paradigm change.
The other tension I mentioned before was between
curiosity-driven research and use-driven research. It would
be useful to give some background to this apparent dichoto-
my between basic and applied research. Some people credit
this artificial separation of basic and applied to Vannevar
Bush, who was the science adviser to President Franklin
Delano Roosevelt, and who in 1945 published an influential
report entitled “Science, the endless frontier” [4,20]. That
report provided the blueprint used by the United States to
develop its biomedical strategy and infrastructure after the
Second World War. Bush recognized that basic science was
the engine that drives any future technological development,
and he was concerned that if the basic science effort was not
protected it would be rapidly “cannibalized” by the more
pressing needs and rapid returns obtained from an applied
research effort. That is how the linear model of research was
formalized, in which basic research leads to applied research
and development, and then to new products or processes.
Bush’s linear model has been challenged by some
authors, including the late Professor Donald Stokes, from
Princeton, who was the author of an extremely interesting
book entitled Pasteur’s Quadrant [18]. Stokes proposed, not
a linear model of research progression, but a two dimension-
al conceptual plane, rescuing the importance of the so-called
“use-inspired basic research”, or what Carlos Morel calls
“strategic research” [17]. Stokes suggested that research
could be inspired by the quest for fundamental understand-
ing, by practical considerations of use, or by both, and these
are represented in the different quadrants of Fig. 3. The upper
left-hand cell includes basic research that is guided solely by
the quest for understanding without thought for practical use.
Stokes called this “the Bohr’s quadrant”, in view of how
clearly Niels Bohr’s quest of a model atomic structure was a
pure voyage of discovery.
The lower right-hand cell includes research that is guided
solely by applied goals without seeking a more general
understanding of the phenomena of a scientific field. Stokes
found appropriate to call it “the Edison’s quadrant”, in view
of how the brilliant inventor of Menlo Park, New Jersey,
never pursued the scientific implications of his many very
practical inventions. Many industries still pursue this type of
research. The upper right-hand quadrant includes basic
research that seeks to expand the frontiers of understanding
but it is also inspired by considerations of use, and Stokes
called it “the Pasteur’s Quadrant”, the title of his book. Note
that Pasteur always considered basic and applied research as
fruits from the same tree, the tree of science. In fact, most of
the current biomedical research and the philosophy of the
Enterprise are framed by Pasteur’s Quadrant, in which there
is no tension between the quest for knowledge and the need
to harness that knowledge to solve practical problems, such
as the development of an HIV vaccine.
Application of the “Enterprise”
model to other global health problems
Currently, two thirds of the world’s 6 billion people live in
developing countries, and more than 1 in 6 persons live on
less than US $1.00 per day. In addition, millions of people die
unnecessarily each year from diseases that are currently treat-
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munity driven “European Developing Countries Clinical
Trials Partnership” (or EDCTP), and the Global HIV/AIDS
Vaccine Enterprise. Mocumbi admonishes us that “[…we are ]
now endangered by a failure to use our collective knowledge,
wisdom and resources to bring essential medical advances to
bear for the benefit of all our citizens.” It is our social respon-
sibility as scientists to do science, not only for the sake of sci-
ence itself, but also for the sake of our fellow human beings
that are suffering the burden of many infectious diseases that
could be effectively controlled if we dedicated our time and
efforts to that noble cause.
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able or preventable. Just three diseases—AIDS, tuberculosis
and malaria—kill 6 million people annually. And access to
existing, effective health interventions is severely limited for
most of those in need, most of them living in developing
countries.
The sad reality is that inadequate attention is paid to the
health problems that affect the majority of the world’s people:
Medical research largely ignores the diseases that kill most
people. Of the US $70 billion spent annually on medical
research, only 10 per cent is devoted to the diseases that cause
90 per cent of global diseases and death. Product development
is primarily focused on rich world diseases. Of nearly 1,400
drugs approved in the last 25 years by the US Food and Drug
Administration (FDA), only 20 were specifically for diseases
that disproportionately affect the developing world.
Recognizing this situation, other collaborative Enter-
prise-like approaches are being implemented or discussed, to
address at least two of the other main killers of mankind,
tuberculosis and malaria. These include “The Global Alliance
for TB Drug Development” and, still under initial planning,
“The Malaria Vaccine Technology Roadmap”.
Concluding remarks
I want to conclude with a quote from my dear friend and col-
league, Pascoal Mocumbi, Former Prime Minister of
Mozambique, and now a very active participant and leader of
two major health research initiatives, the European Com-
Fig. 3. Sources of research inspiration. Adapted
from D.E. Stokes, Pasteur’s Quadrant (1997).I
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Iniciativa Conjunta por una Vacuna contra
el SIDA
Resumen. El sida, cuya existencia era desconocida hace veinticinco años,
se ha convertido en la enfermedad infecciosa más grave a escala planetaria.
El desarrollo de una vacuna contra el virus de la inmunodeficiencia humana
(HIV) es uno de lo retos más difíciles que afronta la moderna ciencia de la
biomedicina. Para ello, la comunidad científica ha de organizarse realizando
un esfuerzo conjunto intenso y con un objetivo concreto, como el que pro-
pone la Iniciativa Conjunta por una Vacuna contra el Sida. El concepto de
“iniciativa” trata de complementar la creatividad del investigador individual
con un sistema de colaboración que asegure un uso más eficaz de los recur-
sos humanos y financieros para generar conocimiento científico nuevo.
Actualmente se están explorando diferentes modalidades del concepto de
“iniciativa” para el desarrollo de fármacos para el tratamiento de la tuber-
culosis y de vacunas para prevenir la malaria. [Int Microbiol 2005;
8(2):93-101]
Palabras clave: vacuna contra el VIH · SIDA · iniciativa científica ·
epidemiología
Iniciativa Conjunta por uma Vacina contra
a AIDS
Resumo. A aids, cuja existência era desconhecida há vinte e cinco anos,
se transformou na doença infecciosa mais grave a escala planetária. O des-
envolvimento de uma vacina contra o vírus da imunodeficiência humana
(HIV) é um do desafios mais difíceis que enfrenta a moderna ciência da bio-
medicina. Para isso, a comunidade científica há de organizar-se realizando
um esforço conjunto intenso e com um objetivo concreto, como o que pro-
põe a Iniciativa Conjunta por uma Vacina contra a Aids. El conceito de “ini-
ciativa” trata de complementar a criatividade do investigador individual
com um sistema de colaboração que assegure mais um uso eficaz dos recur-
sos humanos e financeiros para gerar conhecimento científico novo.
Atualmente se estão explorando diferentes modalidades do conceito de
“iniciativa” para o desenvolvimento de fármacos para o tratamento da
tuberculose e de vacinas para prevenir a malaria. [Int Microbiol 2005;
8(2):93-101]
Palabras chave: vacina contra o HIV · AIDS · iniciativa científica ·
epidemiologia

